◎ Sugi Atlas

Atlas / Drug / Tocilizumab

Tocilizumab

drug
On this page

Also known as ActemraActemra roactemraATLIZUMABBAT-1806Bat1806BIIB-800Biib800MRAMSB-11456MSB11456R-1569RG-1569RGB-19RGB19RHPM-1RO-4877533RoactemraTocilizumab biosimilar (bat-1806)Tocilizumab biosimilar (msb11456)

Summary

Tocilizumab (CHEMBL1237022) is an approved antibody (ATC L04AC07); indicated across 79 conditions including juvenile idiopathic arthritis and rheumatoid arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L04AC07
  • Indications: 79 conditions
  • Clinical trials: 395

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1237022
NameTocilizumab
TypeAntibody
Max phase4
ATCL04AC07

Also known as: Actemra, Actemra roactemra, ATLIZUMAB, BAT-1806, Bat1806, BAT1806, BIIB-800, Biib800, MRA, MSB-11456, MSB11456, R-1569

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
Interleukin-6 receptorBinding8.6

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

79 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
rheumatoid arthritis4MONDO:0008383EFO:0000685
systemic sclerosis4MONDO:0005100EFO:0000717
immune system disorder4MONDO:0005046EFO:0000540
temporal arteritis4MONDO:0008538EFO:1001209
severe acute respiratory syndrome4MONDO:0005091EFO:0000694
polyarticular juvenile idiopathic arthritis4MONDO:0018456EFO:0009730
cytokine release syndrome4MONDO:0600008
ankylosing spondylitis3MONDO:0005306EFO:0003898
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
Takayasu arteritis3MONDO:0017991EFO:1001857
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
polymyalgia rheumatica3MONDO:0019735EFO:0008518
pneumonia3MONDO:0005249EFO:0003106
lymphoma3MONDO:0005062EFO:0000574
epilepsy3MONDO:0005027EFO:0000474
influenza3MONDO:0005812EFO:0007328
graft versus host disease2MONDO:0013730EFO:0004599
pulmonary arterial hypertension2MONDO:0015924EFO:0001361
uveitis2MONDO:0020283EFO:1001231
dermatomyositis2MONDO:0016367EFO:0000398
leukemia2MONDO:0005059EFO:0000565
plasma cell myeloma2MONDO:0009693EFO:0001378
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
Behcet disease2MONDO:0007191EFO:0003780
neuromyelitis optica2MONDO:0019100EFO:0004256
adult-onset Still disease2MONDO:0019355EFO:0007135
Erdheim-Chester disease2MONDO:0018153EFO:1000926
relapsing polychondritis2MONDO:0019125EFO:1001148
neoplasm2MONDO:0005070EFO:0000616
melanoma2MONDO:0005105EFO:0000756
prostate adenocarcinoma2MONDO:0005082EFO:0000673
viral pneumonia2MONDO:0006012EFO:0007541
macrophage activation syndrome2MONDO:0015545EFO:1001806
major depressive disorder2MONDO:0002009MONDO:0002009
breast neoplasm2MONDO:0021100MONDO:0007254
Castleman disease2MONDO:0015564MONDO:0015564
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
acute respiratory distress syndrome2MONDO:0006502EFO:1000637
Schnitzler syndrome2MONDO:0018304EFO:1001165
lung disorder2MONDO:0005275EFO:0003818
myasthenia gravis2MONDO:0009688EFO:0004991
fibrous dysplasia2MONDO:0000845MONDO:0000845
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
familial Mediterranean fever2MONDO:0018088MONDO:0018088
mantle cell lymphoma2MONDO:0018876EFO:1001469
astrocytoma (excluding glioblastoma)2MONDO:0019781EFO:0000272
viral infectious disease2MONDO:0005108EFO:0000763
polymyositis2MONDO:0019127EFO:0003063
motor neuron disorder2MONDO:0020128EFO:0003782
chronic kidney disease1MONDO:0005300EFO:0003884
HIV infectious disease1MONDO:0005109EFO:0000764
acute myeloid leukemia1MONDO:0018874EFO:0000222
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
hepatocellular carcinoma1MONDO:0007256EFO:0000182
intermediate uveitis1MONDO:0006806EFO:1000986
posterior uveitis1MONDO:0006918EFO:1001119
B-cell acute lymphoblastic leukemia1MONDO:0004947EFO:0000094
neoplasm of mature B-cells1MONDO:0004949EFO:0000096
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
urothelial carcinoma1MONDO:0040679EFO:0008528
ovarian cancer1MONDO:0008170MONDO:0008170
follicular lymphoma1MONDO:0018906MONDO:0018906
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
small cell lung carcinoma1MONDO:0008433EFO:0000702
panuveitis1MONDO:0017255EFO:1001082
B-cell non-Hodgkin lymphoma1MONDO:0015759EFO:1001938
colorectal neoplasm1MONDO:0005335MONDO:0005575

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 395.

Phase distribution

PhaseTrials
PHASE291
PHASE385
Not specified70
PHASE161
PHASE442
PHASE1/PHASE236
PHASE2/PHASE38
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04300686PHASE4RECRUITINGA Pilot Study in Severe Patients With Takayasu Arteritis.
NCT06251076PHASE4RECRUITINGPlan Development for Giving Teclistamab in the Outpatient Setting
NCT06498089PHASE4RECRUITINGA Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu’s Arteritis
NCT06624436PHASE4RECRUITINGImmunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
NCT07609940PHASE4NOT_YET_RECRUITINGAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
NCT01119859PHASE4COMPLETEDA Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
NCT01120366PHASE4COMPLETEDSuccess of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation
NCT01163747PHASE4COMPLETEDA Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
NCT01331837PHASE4COMPLETEDA Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
NCT01491815PHASE4UNKNOWNActive Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
NCT01557374PHASE4COMPLETEDTOward the Lowest Effective DOse of Abatacept or Tocilizumab
NCT01661140PHASE4TERMINATEDA Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
NCT01715831PHASE4COMPLETEDA Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
NCT01717859PHASE4COMPLETEDMusculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab
NCT01734382PHASE4COMPLETEDA Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
NCT02034474PHASE4COMPLETEDTocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
NCT02087696PHASE4UNKNOWNUncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
NCT02353780PHASE4TERMINATEDMechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02466581PHASE4UNKNOWNDose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
NCT02573012PHASE4COMPLETEDStudy to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants
NCT02659150PHASE4TERMINATEDEffect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
NCT02682823PHASE4COMPLETEDTocilizumab Real-Life Human Factors (RLHFs) Validation Study
NCT02765074PHASE4COMPLETEDFilling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis
NCT02843789PHASE4COMPLETEDEvolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy
NCT03100253PHASE4TERMINATEDRheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT03215407PHASE4UNKNOWNThe Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone
NCT03244709PHASE4UNKNOWNTocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
NCT03301883PHASE4COMPLETEDA Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT03726749PHASE4COMPLETEDTocilizumab Plus a Short Prednisone Taper for GCA
NCT03737708PHASE4COMPLETEDA Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
NCT03781310PHASE4UNKNOWNTherapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis
NCT03895879PHASE4UNKNOWNUse of Tocilizumab Drug Levels to Optimize Treatment in RA
NCT04157010PHASE4COMPLETEDTocilizumab REMission in Early RA
NCT04377750PHASE4UNKNOWNThe Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
NCT04730323PHASE4COMPLETEDTOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
NCT04762784PHASE4UNKNOWNA Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
NCT04779047PHASE4UNKNOWNComparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT05133635PHASE4WITHDRAWNHigh-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19
NCT05604859PHASE4UNKNOWNEvaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)
NCT05730777PHASE4UNKNOWNCorrelation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdbgtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot